Oct 28HHS draft policy lets licensed pharmacies compound six peptides, including BPC-157. What changed and what did not.
Skip to content
PeptideAgent

Thymulin regulatory status

Current status of Thymulin in the United States: Not eligible for compounding. In sport: WADA prohibited. Details, sources, and the dated timeline follow.

By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed.  Last verified

What is the current status of Thymulin?

Regulatory: Not eligible for compoundingWADA: WADA prohibitedVerified: Verified Sep 29, 2026
FDA and compounding
Thymulin is not an FDA approved drug. FDA lists thymulin acetate in 503A Category 3, meaning it was nominated for compounding without enough supporting information for FDA to evaluate it. Category 3 substances are not covered by FDA's interim compounding policy, and FDA says it would consider taking action against a compounder that uses them. As of the last verification date, thymulin is not on the 503A bulks list, so a US compounding pharmacy has no federal basis to compound it from bulk. It does not appear on FDA's 503B nomination lists, so outsourcing facilities have no route for it either. It was not part of the July 2026 advisory committee review.
WADA
WADA prohibited
Access path
  1. No lawful United States access path identified on the last verified date: it is not FDA approved and is not on the 503A bulks list.
  2. Not available as an FDA approved product, not nominated for the 503A bulks list, and not eligible for compounding under section 503A or 503B.
  3. Products labeled research use only are unapproved drugs when sold for human use and are not verified for identity or purity.

Full Thymulin page: evidence, dosing in the literature, and sources

How has the status of Thymulin changed over time?

No dated regulatory event has been recorded for Thymulin. That usually means no FDA, PCAC, Federal Register, or WADA action has named it specifically. Category-wide actions are listed on the tracker hub.

Sources

Numbered citations in the answers above point here, followed by the regulatory sources on record for Thymulin and the source of each dated event.

  1. [1]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA, 2026
  2. [2]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2 list, content current as of April 22, 2026)FDA, 2026
  3. [3]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
  4. [4]FDA warning letter 735063, August 24, 2026, to an online seller of research-use-only peptides: products labeled research use only were unapproved new drugs (FDA warning letters database)FDA, 2026